Patients with protein energy wasting syndrome undergoing hemodialysis. Chronic kidney disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 25 patients, as prescribed and under the supervision of a nutritionist and nephrologist, use VM protein powder for three months. VM-protein 24 grams orally, manufac
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic kidney disease (CKD) who are undergoing chronic hemodialysis for at least 6 months. Diagnosis of protein-energy wasting syndrome based on international criteria Weight loss = 5% in the last 3 months or body mass index less than 23 Decreased muscle mass based on BIA measurement or SGA index Decreased serum albumin (<3.8 g/dL) or decreased serum TIBC level (<200 mg/dL) Reduced energy and protein intake (<25 kcal/kg/day and <1.0 g/kg/day) Receiving erythropoietin treatment for at least the last 3 months Written consent to participate in the study
Exclusion criteria
Exclusion criteria: Acute inflammatory diseases or active infections Malignant diseases (active cancer) or receiving chemotherapy Anemia due to non-renal causes (MDS hemoglobinopathy) Taking steroids or immunosuppressant drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum erythropoietin changes. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;Erythropoietin resistance index. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;Serum hemoglobin level. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;Changes in serum albumin and TIBC levels. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;Changes in serum ferritin levels. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;CRP and ESR changes. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: Blood sample and laboratory examination.;Changes in body analysis indicators. Timepoint: At the beginning of the study and three months after consuming the protein powder. Method of measurement: InBody S10 device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhazale Ghorbani Garakani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed